Therapeutic potential of novel selective drugs targeting nicotinic acetylcholine receptors

J Mol Neurosci. 2006;30(1-2):17-8. doi: 10.1385/JMN:30:1:17.

Abstract

The potential therapeutic benefit of nicotinic ligands in a variety of neurodegenerative pathologies involving the CNS has energized research efforts to develop nicotinic acetylcholine receptor (nAChR) subtype-selective ligands (Bencherif and Schmitt, 2005). In particular, there has been a concerted effort to develop nicotinic compounds with selectivity for CNS nAChRs as potential pharmaceutical tools in the management of these disorders. Clinical and experimental data demonstrate a central role for alpha7 and alpha4beta2 nAChRs in cognitive function, sensory processing, mood, and neuroprotection (Bencherif and Schmitt, 2005; Buccafusco et al., 2005). The development of safe alpha7-selective ligands has been hampered by their lack of discrimination with hERG channels and 5-HT3 receptors. We have developed a number of compounds that display nanomolar affinity to the alpha7 and/or the alpha4beta2 receptor. Investigation of alpha7 functional activity showed a full range of activities from antagonists to full agonists without any significant activity at the human 5-HT3 receptor, P450 isozymes, hERG channels, or in the AMES test. Our findings demonstrate that potent and highly selective nAChR ligands can be designed.

MeSH terms

  • Animals
  • Cholinergic Agents / pharmacology
  • Cholinergic Agents / therapeutic use*
  • Cognition / drug effects
  • Cognition / physiology
  • Dizocilpine Maleate / therapeutic use
  • Humans
  • Ligands
  • Neuroprotective Agents / pharmacology
  • Neuroprotective Agents / therapeutic use
  • Receptors, Nicotinic / drug effects
  • Receptors, Nicotinic / physiology*

Substances

  • Cholinergic Agents
  • Ligands
  • Neuroprotective Agents
  • Receptors, Nicotinic
  • Dizocilpine Maleate